A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer

This study has been withdrawn prior to enrollment.

(Study closed by Protocol Review Monitoring Committee because of lack of accrual)

Sponsor:

Collaborator:

Novartis

Information provided by (Responsible Party):

University of Kansas

ClinicalTrials.gov Identifier:

NCT01163929

First received: July 14, 2010

Last updated: October 22, 2012

Last verified: October 2012

No Study Results Posted on ClinicalTrials.gov for this Study

Study was withdrawn before participants were enrolled.

Study Status:	This study has been withdrawn prior to enrollment.
Study Completion Date:	March 2012
Primary Completion Date:	March 2012 (Final data collection date for primary outcome measure)